Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

BackgroundThe combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanthem...

Full description

Bibliographic Details
Main Authors: Katharina C. Kähler, Ralf Gutzmer, Friedegrund Meier, Lisa Zimmer, Markus Heppt, Anja Gesierich, Kai-Martin Thoms, Jochen Utikal, Jessica C. Hassel, Carmen Loquai, Claudia Pföhler, Lucie Heinzerling, Martin Kaatz, Daniela Göppner, Annette Pflugfelder, Ann-Sophie Bohne, Imke Satzger, Lydia Reinhardt, Jan-Malte Placke, Dirk Schadendorf, Selma Ugurel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
melanoma
vemurafenib
cobimetinib
BRAF/MEK inhibition
skin toxicity
therapy outcome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.672172/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.672172/full

Similar Items